ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

9473	Companies
185416	Keywords
117771	Articles
99291	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 07/08/2024 at 07:56, 1 year 4 months ago

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment

COVID-19 Treatment Phase 2 Study AB Science Masitinib
BRIEF

published on 06/28/2024 at 12:36, 1 year 5 months ago

AB Science provides an update on the application for authorization of masitinib in ALS

ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 12:31, 1 year 5 months ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations

AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF

published on 06/27/2024 at 10:20, 1 year 5 months ago

AB Science - Results of the Combined General Meeting of June 26, 2024

Shareholders Share Capital Resolutions General Assembly AB Science
BRIEF

published on 05/17/2024 at 18:03, 1 year 6 months ago

Correction of the Consolidated Accounts of AB Science for 2023

Financial Results Research And Development Consolidated Accounts AB Science Accounting Correction
BRIEF

published on 05/15/2024 at 20:21, 1 year 6 months ago

Reduction in operational losses and significant advances in clinical development for AB Science in 2023

Financial Results Clinical Development AB Science Masitinib Amyotrophic Lateral Sclerosis
PRESS RELEASE

published on 05/15/2024 at 20:16, 1 year 6 months ago

AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science presents financial information for the year 2023, including clinical development updates and intellectual property strengthening. Consolidated operating loss decreased by 15.7% compared to 2022

Financial Information Clinical Development Intellectual Property Operating Loss AB Science

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 15 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 20 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 50 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 45 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 50 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:30, 20 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 44 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 49 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 50 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 50 minutes ago

Official List Notice

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 5 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 50 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 5 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 5 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE